'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Respiratory Syncytial Virus (RSV) Infections 29
Dec 14, 2016: Medivir fusion inhibitor for the treatment of Respiratory Syncytial Virus infection, MIV-323, enters non-clinical development 29
Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine 29
Nov 07, 2016: Mucosis Initiates First-in-Human Study of SynGEM, a Needle-Free Nasal Spray RSV Vaccine 29
Oct 31, 2016: ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus 30
Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine 30
Oct 13, 2016: Immunovaccine Announces Positive Phase 1 Topline Data for DepoVax based Respiratory Syncytial Virus Vaccine Candidate 31
Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium 32
Clinical Trial Profile Snapshots 33
Appendix 132
Abbreviations 132
Definitions 132
Research Methodology 133
Secondary Research 133
About GlobalData 134
Contact Us 134
Disclaimer 134
Source 135
List of Tables
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials by Region, 2016* 6
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Respiratory Syncytial Virus (RSV) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Respiratory Syncytial Virus (RSV) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Respiratory Syncytial Virus (RSV) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Respiratory Syncytial Virus (RSV) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Respiratory Syncytial Virus (RSV) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
List of Figures
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
Respiratory Syncytial Virus (RSV) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Respiratory Syncytial Virus (RSV) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
Respiratory Syncytial Virus (RSV) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Respiratory Syncytial Virus (RSV) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Respiratory Syncytial Virus (RSV) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Respiratory Syncytial Virus (RSV) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Respiratory Syncytial Virus (RSV) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 133